Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

Zeina Ayoub, Therese Andraos, Sarah A. Milgrom, Chelsea C. Pinnix, Bouthaina S. Dabaja, Sweet Ping Ng, Jillian R. Gunther, Joseph D. Khoury, Nathan H. Fowler, Satva S. Neelapu, Felipe Samaniego, Luis E. Fayad, Loretta J. Nastoupil

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was 55 years. At a median follow-up of 65 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 76.6% and 87.6%, respectively. Patients receiving systemic therapy followed by radiation therapy (RT) had a significantly better PFS (p=.003) than those treated with RT alone, but similar OS (p =.476). Patients treated with RT had 100% local control. Compared to 132 patients with grade 1–2 FL, those with FL3 had similar PFS (p =.493) and OS (p =.330). Patients with FL3 can experience favorable outcomes when treated with a combination of systemic therapy and RT, comparable to low grade FL.

Original languageEnglish (US)
Pages (from-to)2432-2440
Number of pages9
JournalLeukemia and Lymphoma
Volume60
Issue number10
DOIs
StatePublished - Aug 24 2019

Keywords

  • Follicular lymphoma
  • chemotherapy
  • radiation
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy'. Together they form a unique fingerprint.

Cite this